CureVac N.V. (CVAC) Expected to Beat Earnings Estimates: Should You Buy?

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for CureVac N.V. (CVAC) due to higher revenues, with a focus on how actual results compare to estimates impacting stock price [1] Earnings Expectations - CureVac is expected to report a quarterly loss of $0.28 per share, reflecting a year-over-year change of +15.2$10.07 million, which is an increase of 22.1% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4] - The Most Accurate Estimate for CureVac is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +7.14%, suggesting a bullish outlook from analysts [10] Earnings Surprise Prediction - A positive Earnings ESP reading is a strong indicator of a potential earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8] - CureVac currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [11] Historical Performance - In the last reported quarter, CureVac was expected to post a loss of $0.22 per share but actually reported a loss of$0.34, resulting in a surprise of -54.55% [12] - Over the past four quarters, CureVac has only beaten consensus EPS estimates once [13] Conclusion - CureVac is viewed as a compelling candidate for an earnings beat, but investors should consider other factors before making investment decisions [16]